Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Neoplasms 4Neoplasm Metastasis 3Urinary Bladder Neoplasms 2Recurrence 2Urethral Neoplasms 1Ureteral Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Multiple Myeloma 1Melanoma 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1

Interventions

Dexamethasone 33Cyclophosphamide 31fludarabine 19venetoclax 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × ALT-801 × Clear all
NCT01625260 2024-07-19

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Altor BioScience

Phase 1/2 Terminated
12 enrolled 13 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Recurrence

NCT01670994 2024-06-18

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Altor BioScience

Phase 1/2 Terminated
6 enrolled 10 charts
Plasma cell

Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡